• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

移植物抗宿主病对成人T细胞白血病-淋巴瘤异基因造血细胞移植的影响:聚焦预处理方案的全国性回顾性研究

Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.

作者信息

Ishida Takashi, Hishizawa Masakatsu, Kato Koji, Tanosaki Ryuji, Fukuda Takahiro, Takatsuka Yoshifusa, Eto Tetsuya, Miyazaki Yasushi, Hidaka Michihiro, Uike Naokuni, Miyamoto Toshihiro, Tsudo Mitsuru, Sakamaki Hisashi, Morishima Yasuo, Suzuki Ritsuro, Utsunomiya Atae

机构信息

Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

出版信息

Biol Blood Marrow Transplant. 2013 Dec;19(12):1731-9. doi: 10.1016/j.bbmt.2013.09.014. Epub 2013 Sep 30.

DOI:10.1016/j.bbmt.2013.09.014
PMID:24090597
Abstract

Allogeneic hematopoietic cell transplantation (HCT), but not autologous HCT, can provide long-term remission in some patients with adult T cell leukemia-lymphoma (ATL). We retrospectively analyzed the effects of acute graft-versus-host disease (GVHD) among the 616 patients with ATL who survived at least 30 days after allogeneic HCT with other than cord blood grafts. Multivariate analyses treating the occurrence of GVHD as a time-varying covariate demonstrated an association between grade I-II acute GVHD and favorable overall survival (OS) (hazard ratio [HR], 0.634; 95% confidence interval [CI], 0.477 to 0.843), whereas grade III-IV acute GVHD showed a trend toward unfavorable OS (HR, 1.380; 95% CI, 0.988 to 1.927) compared with nonacute GVHD. In subsequent multivariate analyses of patients who survived at least 100 days after HCT (n = 431), the presence of limited chronic GVHD showed a trend toward favorable OS (HR, 0.597; 95% CI, 0.354 to 1.007), and extensive chronic GVHD had a significant effect on OS (HR, 0.585; 95% CI, 0.389 to 0.880). There were no significant interactions between myeloablative conditioning or reduced-intensity conditioning with OS even when acute GVHD was absent or present at grade I-II or grade III-IV or when chronic GVHD was absent, limited, or extensive. This study demonstrates the actual existence of graft-versus-ATL effects in patients with ATL regardless of whether myeloablative conditioning or reduced-intensity conditioning is used.

摘要

异基因造血细胞移植(HCT)而非自体HCT,可使部分成人T细胞白血病 - 淋巴瘤(ATL)患者获得长期缓解。我们回顾性分析了616例接受非脐血移植物的异基因HCT后至少存活30天的ATL患者中急性移植物抗宿主病(GVHD)的影响。将GVHD的发生作为时变协变量的多因素分析表明,I - II级急性GVHD与良好的总生存期(OS)相关(风险比[HR],0.634;95%置信区间[CI],0.477至0.843),而与非急性GVHD相比,III - IV级急性GVHD显示出OS不良的趋势(HR,1.380;95% CI,0.988至1.927)。在对HCT后至少存活100天的患者(n = 431)进行的后续多因素分析中,局限性慢性GVHD的存在显示出OS良好的趋势(HR,0.597;95% CI,0.354至1.007),广泛性慢性GVHD对OS有显著影响(HR,0.585;95% CI,0.389至0.880)。即使不存在急性GVHD或急性GVHD为I - II级或III - IV级,或者不存在、局限性或广泛性慢性GVHD时,清髓性预处理或减低强度预处理与OS之间也没有显著的相互作用。本研究表明,无论采用清髓性预处理还是减低强度预处理,ATL患者中实际存在移植物抗ATL效应。

相似文献

1
Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.移植物抗宿主病对成人T细胞白血病-淋巴瘤异基因造血细胞移植的影响:聚焦预处理方案的全国性回顾性研究
Biol Blood Marrow Transplant. 2013 Dec;19(12):1731-9. doi: 10.1016/j.bbmt.2013.09.014. Epub 2013 Sep 30.
2
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.急性白血病患者 HLA 全相合同胞异基因造血干细胞移植中,减低剂量预处理方案与清髓性预处理方案的比较结果:单中心经验
Transfus Apher Sci. 2013 Dec;49(3):590-9. doi: 10.1016/j.transci.2013.07.030. Epub 2013 Aug 8.
3
Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.异基因造血干细胞移植后移植物抗宿主病对急性髓系白血病的影响:来自欧洲血液和骨髓移植组急性白血病工作组的报告。
Leukemia. 2012 Dec;26(12):2462-8. doi: 10.1038/leu.2012.135. Epub 2012 May 22.
4
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
5
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.高危急性白血病异基因造血干细胞移植中标准与替代清髓性预处理方案的比较
Haematologica. 2002 Jan;87(1):52-8.
6
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.马利兰剂量强度与骨髓增生异常综合征或急性髓系白血病患者行减低强度异基因外周血造血干细胞移植的结局。
Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.
7
Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.异基因造血细胞移植治疗成人 T 细胞白血病后移植物抗宿主病对结局的影响:一项回顾性队列研究。
Blood. 2012 Mar 1;119(9):2141-8. doi: 10.1182/blood-2011-07-368233. Epub 2012 Jan 10.
8
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years.近年来,IV 级急性移植物抗宿主病患者与治疗相关的死亡率和总生存率有所改善。
Biol Blood Marrow Transplant. 2016 May;22(5):910-8. doi: 10.1016/j.bbmt.2015.12.024. Epub 2015 Dec 31.
9
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.异基因干细胞移植治疗成人骨髓增生异常综合征:移植前疾病负担的重要性。
Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.
10
Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植改善成人T细胞白血病/淋巴瘤的预后。
Bone Marrow Transplant. 2001 Jan;27(1):15-20. doi: 10.1038/sj.bmt.1702731.

引用本文的文献

1
Clinical significance of NOTCH1 and FBXW7 alterations in adult T-cell leukemia/lymphoma.NOTCH1和FBXW7改变在成人T细胞白血病/淋巴瘤中的临床意义
Int J Hematol. 2025 Feb;121(2):206-221. doi: 10.1007/s12185-024-03880-3. Epub 2024 Nov 25.
2
Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.异体造血干细胞移植后莫格利珠单抗治疗 T 细胞淋巴瘤患者:一项回顾性分析。
Int J Hematol. 2024 Jun;119(6):736-744. doi: 10.1007/s12185-024-03753-9. Epub 2024 Mar 27.
3
Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma.
人嗜T淋巴细胞病毒1型相关北美成人T细胞白血病/淋巴瘤的干细胞移植结果
Clin Hematol Int. 2023 Jun;5(2-3):78-91. doi: 10.1007/s44228-023-00032-y. Epub 2023 Mar 15.
4
CCR7 alterations associated with inferior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.CCR7 改变与莫格利珠单抗治疗成人 T 细胞白血病/淋巴瘤不良预后相关。
Hematol Oncol. 2022 Dec;40(5):876-884. doi: 10.1002/hon.3072. Epub 2022 Sep 6.
5
Clinicopathological significance of CD28 overexpression in adult T-cell leukemia/lymphoma.CD28 过表达在成人 T 细胞白血病/淋巴瘤中的临床病理意义。
Cancer Sci. 2022 Jan;113(1):349-361. doi: 10.1111/cas.15191. Epub 2021 Nov 29.
6
Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.成人T细胞白血病/淋巴瘤中TP53突变的临床意义
Br J Haematol. 2021 Nov;195(4):571-584. doi: 10.1111/bjh.17749. Epub 2021 Aug 17.
7
Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.自体和异体造血干细胞移植治疗复发/难治性 B 细胞非霍奇金淋巴瘤患者的生存比较:一项荟萃分析。
Cell Transplant. 2020 Jan-Dec;29:963689720975397. doi: 10.1177/0963689720975397.
8
Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.成人 T 细胞白血病/淋巴瘤中 CD28 基因相关激活改变的临床意义。
Br J Haematol. 2021 Jan;192(2):281-291. doi: 10.1111/bjh.17211. Epub 2020 Nov 18.
9
Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.免疫组织化学分析 CCR4 羧基末端可预测成人 T 细胞白血病/淋巴瘤中 CCR4 突变和 mogamulizumab 的疗效。
J Pathol Clin Res. 2021 Jan;7(1):52-60. doi: 10.1002/cjp2.180. Epub 2020 Oct 6.
10
Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma-Romanian Experience.成人T细胞白血病/淋巴瘤的异基因干细胞移植——罗马尼亚经验
J Clin Med. 2020 Jul 28;9(8):2417. doi: 10.3390/jcm9082417.